BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)

Last updated: January 20, 2025
Sponsor: Terumo Europe N.V.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Carcinoma

Treatment

BioPearl™

Clinical Study ID

NCT05911633
T144E3
  • Ages > 18
  • All Genders

Study Summary

The primary objective of the study is to confirm safety and technical success of BioPearl™ microspheres loaded with Doxorubicin in the treatment of unresectable hepatocellular carcinoma (HCC). The secondary objective of the study is to investigate the efficacy of BioPearl™ microspheres loaded with Doxorubicin in the treatment of subjects with unresectable HCC.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Subject is at least 18 years old

  2. Subject with HCC confirmed by histology or according to the latest applicableversion of EASL (the European Association for the Study of the Liver) criteria

  3. Subject with tumor(s) < 5 cm and within the up-to-7 criteria: the sum of thediameter of the largest tumor (in cm) and the number of tumors must be ≤ 7.0

  4. Subject with BCLC (Barcelona Clinic Liver Cancer) Stage A or B classification who isnot a candidate for curative treatment at the time of study inclusion

  5. Subject with treatment failure/recurrence after a prior resection/ablation ispermitted, with the exception of recurrence in the segment of a prior thermalablation

  6. WHO (World Health Organization) or ECOG (Eastern Cooperative Oncology Group)performance status 0 or 1

  7. Subject deemed treatable in one session for initial treatment

  8. Normal liver or compensated cirrhosis with preserved liver function (Child-PughClass A)

  9. Total bilirubin ≤ 2.0 mg/dl

  10. Adequate bone marrow function: Hemoglobin ≥ 9g/dl, absolute neutrophil count ≥ 1.0 x 109/L, platelet count ≥ 75 x 109/L

  11. Subject with no ascites or with minor ascites controlled by sodium dietaryrestrictions (subject receiving diuretic treatment or paracentesis is not eligible)

  12. Adequate renal function: serum creatinine < 1.5 X ULN (Upper Limit of Normal)

  13. Subject has provided written informed consent

  14. Subjects of childbearing/reproductive potential should use adequate birth controlmeasures, during the study treatment period until survival follow-up

Exclusion

Exclusion Criteria:

  1. Subject previously treated with any systemic therapy for HCC

  2. Subject previously treated with intra-arterial loco-regional therapy for HCC

  3. Eligible for curative treatment at the time of study inclusion

  4. Recurrence in the segment of a prior thermal ablation

  5. Advanced liver disease: Child-Pugh's B-C class or active gastrointestinal bleeding,encephalopathy

  6. Advanced tumoral disease: BCLC class C or D (vascular invasion - even segmental,extra-hepatic spread or cancer-related symptoms performance status >1)

  7. History of another primary tumor. Exceptions include: A. Malignancy treated with curative intent ≥ 5 years before inclusion and with noknown active disease B. Malignancy which occurred < 5 years before, not active and not expected to recuror be clinically relevant in the next 5 years

  8. Subject with history of biliary tree disease or biliary dilatation

  9. Portal vein thrombosis, porto-systemic shunt, hepatofugal blood flow or absentportal blood flow in the liver area to be treated

  10. Contraindication to multiphasic CT and MRI (e.g. allergy to contrast media)

  11. Any other contraindication for embolization procedure or Doxorubicin treatment

  12. Subject is currently participating in an investigational drug or device study thathas not completed the primary endpoint or that clinically interferes with thecurrent study endpoints Note: Trials requiring extended follow-up for products that were investigational,but have become commercially available since then, are not consideredinvestigational trials

  13. In the Investigator's opinion subject has (a) co-morbid condition(s) that couldlimit the subject's ability to participate in the study, compliance with follow-uprequirements or impact the scientific integrity of the study

  14. Pregnant or breast-feeding woman

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: BioPearl™
Phase:
Study Start date:
February 27, 2024
Estimated Completion Date:
December 30, 2027

Study Description

This is a prospective, single arm, multi-centre, post-market clinical follow-up study to further assess safety and efficacy in 50 subjects with unresectable HCC treated with BioPearl™ microspheres loaded with Doxorubicin. All subjects will undergo clinical follow-up until disease progression and/or next treatment option, after which subjects will be followed for survival. Subjects will be followed up to a maximum of 18 months. An intermediate analysis will take place during enrollment period on safety and technical success to support regulatory requirements.

Connect with a study center

  • CUB Hôpital Erasme

    Brussels,
    Belgium

    Active - Recruiting

  • UZ Leuven

    Leuven,
    Belgium

    Active - Recruiting

  • Beaujon Hospital

    Clichy,
    France

    Active - Recruiting

  • CHU Grenobles (Hôpital Michallon)

    La Tronche,
    France

    Site Not Available

  • Paul-Brousse Hospital

    Villejuif,
    France

    Active - Recruiting

  • SLK-Kliniken Heilbronn

    Heilbronn,
    Germany

    Active - Recruiting

  • University Hospital Tübingen

    Tübingen,
    Germany

    Active - Recruiting

  • Fondazione IRCCS Instituto Tumori

    Milan,
    Italy

    Active - Recruiting

  • Fondazione Policlinico Universitario A. Gemelli

    Rome,
    Italy

    Active - Recruiting

  • Città della Salute e della Scienza di Torino

    Turin,
    Italy

    Active - Recruiting

  • Città della Salute e della Scienza di Torino Presidio Molinette

    Turin,
    Italy

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.